Protocols
9 protocol(s) meet the specified criteria
Disease Site: Melanoma, skin
Protocol No.TitleStatus
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
AMG232-20120238A Phase 1b/2 Study Evaluation of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous MelanomaOpen
ECOG1609-CIRBA Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Vs High Dose Interferon alpha2b for Resected High-Risk Melanoma Open (affiliates only)
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC1531Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of use of 11Cmethyl-L-tryptophan (AMT) PET at Baseline as a Predictive Imaging Biomarker of ResponseOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NCI9922A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance Open